Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
Rituximab 375 mg/m(2) weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50 x 10(9)/L) and comple...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2008
|
| 在線閱讀: | https://doi.org/10.3324/haematol.12206 https://haematologica.org/article/download/4889/19734 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|